Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
From Marseille to MontThe FAA investigates after Boeing says workers in South Carolina falsified 787 inspection recordsVietnam celebrates 70 years since Dien Bien Phu battle that ended French colonial ruleShaquille O'Neal kept 'going missing' says exFBI lays out detailed case against Florida man accused in wife's disappearance in SpainHugh Jackman's kids 'worried' about the actor after his split from DeborraWomen SLAM the skyrocketing price of professional lash extensionsWoods Richardson allows 1 hit in 6 shutout innings with 8 strikeouts as Twins beat Mariners 3Madonna fans hail the 'iconic' ageGerard Butler appears in high spirits as he watches Chelsea FC thrash West Ham 5
0.163s , 6497.875 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,Global Gleam news portal